ZIM
LGND icon

Zacks Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Zacks Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,452
Closed -$826K – 667
2023
Q2 		$826K Buy
11,452
+1,479
+15% +$111K 0.01% 399
2023
Q1 		$734K Buy
+9,973
New +$709K 0.01% 410
2020
Q4 		– Sell
-6,428
Closed -$382K – 554
2020
Q3 		$382K Buy
6,428
+83
+1% +$5.66K 0.01% 429
2020
Q2 		$443K Buy
+6,345
New +$402K 0.01% 401
2019
Q1 		– Sell
-11,522
Closed -$975K – 574
2018
Q4 		$975K Sell
11,522
-1,626
-12% -$173K 0.02% 349
2018
Q3 		$2.25M Sell
13,148
-1,184
-8% -$179K 0.05% 250
2018
Q2 		$1.85M Buy
+14,332
New +$1.6M 0.04% 290
2018
Q1 		– Sell
-13,276
Closed -$1.13M – 576
2017
Q4 		$1.13M Sell
13,276
-766
-5% -$66.4K 0.02% 374
2017
Q3 		$1.19M Buy
+14,042
New +$1.11M 0.03% 338
2016
Q2 		– Sell
-3,943
Closed -$263K – 679
2016
Q1 		$263K Buy
+3,943
New +$240K 0.01% 516
2015
Q4 		– Sell
-5,535
Closed -$296K – 613
2015
Q3 		$296K Buy
+5,535
New +$336K 0.01% 513

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zacks Investment Management's LGND Position: Q3 2023 in Review

Zacks Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2023, closing a stake of 11,452 shares — an estimated $826K sold.

Zacks Investment Management first reported a position in LGND in Q3 2015 and held it in 11 quarters. The position peaked at $2.25M in Q3 2018. 196 funds tracked by Wall St. Rank hold LGND as of Q3 2023.

  • Zacks Investment Management reported no remaining Ligand Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Zacks Investment Management sold 11,452 Ligand Pharmaceuticals shares in Q3 2023, an estimated $826K.
  • Zacks Investment Management first reported a position in Ligand Pharmaceuticals in Q3 2015 and held it in 11 quarters.
  • Zacks Investment Management's Ligand Pharmaceuticals position peaked at $2.25M in Q3 2018.
  • 196 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2023.

Based on Zacks Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.